Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis.

ABSTRACT:

Introduction

Chemotherapy-induced thrombocytopenia (CIT) is a significant challenge in cancer treatment, often leading to dose reductions and reduced number of cycles. The limited effectiveness of platelet transfusions in managing CIT highlights the need for alternative treatments. Thrombopoietin receptor agonists (TPO-RA), including romiplostim, eltrombopag and avatrombopag, have shown potential in increasing platelet counts in CIT patients, necessitating a comprehensive analysis of their efficacy.

Methods

This meta-analysis followed the Preferred Reporting Items for Systemic Reviews and Meta-analysis guidelines, searching Ovid databases up to 5 October 2023. The primary metric of interest was platelet count changes post-TPO-RA administration in CIT patients.

Results

SUBMITTER: Gurumurthy G 

PROVIDER: S-EPMC11771093 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature